Secondary Objectives: 1. To assess the frequency and severity of toxicities associated with this treatment. 2. To evaluate overall survival and progression-free survival in patients with recurrent or metastatic head and neck cancer treated with single agent Abraxane. 3.To assess whether the addition of Centuximab will re-sensitize head and neck cancer to Abraxane after progression on single agent Abraxane.